论文部分内容阅读
目的对阿莫西林克拉维酸钾治疗社区获得性肺炎(CAP)进行疗效观察及药物经济学评价。方法阿莫西林克拉维酸钾联合左氧氟沙星为治疗组,氨苄西林舒巴坦联合左氧氟沙星为对照组。比较临床疗效,计算细菌学清除率,安全性及药物价格评价。结果162例CAP患者中,治疗组81例痊愈率和总有效率分别为70.37%和91.35%,细菌清除率为87.65%,药物不良反应发生率为7.41%;对照组81例痊愈率和总有效率分别为66.67%和88.89%,细菌清除率为85.19%,药物不良反应发生率为9.88%;两组比较差异无统计学意义(P>0.05),平均疗程、住院天数和住院费用差异无统计学意义(P>0.05),试验组成本-效果比是30∶46,低于对照组38∶82。结论阿莫西林克拉维酸钾联合左氧氟沙星治疗CAP临床疗效较好,药物不良反应低,成本-效果比较低。
Objective To evaluate the efficacy of amoxicillin and clavulanate in the treatment of community-acquired pneumonia (CAP). Methods Amoxicillin and clavulanate potassium combined with levofloxacin as the treatment group, ampicillin and sulbactam combined with levofloxacin as the control group. Compare clinical efficacy, calculate bacteriological clearance rate, safety and drug price evaluation. Results Among the 162 patients with CAP, the cure rate and total effective rate of 81 patients in treatment group were 70.37% and 91.35% respectively, the bacterial clearance rate was 87.65% and the incidence of adverse drug reactions was 7.41%. In control group, the cure rate and total (66.67% and 88.89% respectively), bacterial clearance rate was 85.19% and adverse drug reaction rate was 9.88%. There was no significant difference between the two groups (P> 0.05). There was no statistical difference between the average course of treatment, hospitalization days and hospitalization costs Significance (P> 0.05), the test group cost - effect ratio is 30:46, lower than the control group 38:82. Conclusion Amoxicillin and clavulanate potassium combined with levofloxacin in the treatment of CAP has better curative effect, less adverse drug reactions and lower cost-effectiveness.